首页 > 最新文献

Respiratory investigation最新文献

英文 中文
Association of poor sleep quality with clinical variables in nontuberculous mycobacterial pulmonary disease
IF 2.4 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-30 DOI: 10.1016/j.resinv.2025.01.005
Yuki Toyoda , Mitsuru Tabusadani , Yusuke Matsumura , Kosuke Mori , Kazuki Ono , Kazuma Kawahara , Shunya Omatsu , Koji Furuuchi , Keiji Fujiwara , Kozo Morimoto , Hideaki Senjyu , Ryo Kozu

Background

The high prevalence of poor sleep quality in patients with chronic respiratory diseases makes it an important clinical topic. However, the prevalence and characteristics of poor sleep quality in those with nontuberculous mycobacterial pulmonary disease and its association with clinical variables remain unclear.

Methods

This retrospective study involved patients with nontuberculous mycobacterial pulmonary disease between June 2017 and May 2022. The prevalence of poor sleep quality was measured by the Pittsburgh Sleep Quality Index was used to and its association with clinical variables including age, sex, laboratory data, pulmonary function, respiratory symptoms, mental health, health-related quality of life, and physical function was assessed.

Results

The median age of 233 participants was 65 years, with poor sleep quality present in 123 patients (52.8%) who were older, female, and unemployed with dyspnea, anxiety symptoms, low health-related quality of life, and low exercise capacity. Many reported that they "cannot get to sleep within 30 min," "wake up in the middle of the night or early morning," "have to get up to use the bathroom," "cannot breathe comfortably," or "cough or snore loudly." Multivariate logistic regression analysis indicated a significant association between poor sleep quality, female sex, and low health-related quality of life.

Conclusion

Our results suggested that for the patients in this study, a multidisciplinary management that considers poor sleep quality is required and assessment of sleep quality as a screening is needed.
{"title":"Association of poor sleep quality with clinical variables in nontuberculous mycobacterial pulmonary disease","authors":"Yuki Toyoda ,&nbsp;Mitsuru Tabusadani ,&nbsp;Yusuke Matsumura ,&nbsp;Kosuke Mori ,&nbsp;Kazuki Ono ,&nbsp;Kazuma Kawahara ,&nbsp;Shunya Omatsu ,&nbsp;Koji Furuuchi ,&nbsp;Keiji Fujiwara ,&nbsp;Kozo Morimoto ,&nbsp;Hideaki Senjyu ,&nbsp;Ryo Kozu","doi":"10.1016/j.resinv.2025.01.005","DOIUrl":"10.1016/j.resinv.2025.01.005","url":null,"abstract":"<div><h3>Background</h3><div>The high prevalence of poor sleep quality in patients with chronic respiratory diseases makes it an important clinical topic. However, the prevalence and characteristics of poor sleep quality in those with nontuberculous mycobacterial pulmonary disease and its association with clinical variables remain unclear.</div></div><div><h3>Methods</h3><div>This retrospective study involved patients with nontuberculous mycobacterial pulmonary disease between June 2017 and May 2022. The prevalence of poor sleep quality was measured by the Pittsburgh Sleep Quality Index was used to and its association with clinical variables including age, sex, laboratory data, pulmonary function, respiratory symptoms, mental health, health-related quality of life, and physical function was assessed.</div></div><div><h3>Results</h3><div>The median age of 233 participants was 65 years, with poor sleep quality present in 123 patients (52.8%) who were older, female, and unemployed with dyspnea, anxiety symptoms, low health-related quality of life, and low exercise capacity. Many reported that they \"cannot get to sleep within 30 min,\" \"wake up in the middle of the night or early morning,\" \"have to get up to use the bathroom,\" \"cannot breathe comfortably,\" or \"cough or snore loudly.\" Multivariate logistic regression analysis indicated a significant association between poor sleep quality, female sex, and low health-related quality of life.</div></div><div><h3>Conclusion</h3><div>Our results suggested that for the patients in this study, a multidisciplinary management that considers poor sleep quality is required and assessment of sleep quality as a screening is needed.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 2","pages":"Pages 210-215"},"PeriodicalIF":2.4,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current drug therapy for pleural mesothelioma 胸膜间皮瘤的药物治疗现状。
IF 2.4 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-15 DOI: 10.1016/j.resinv.2024.12.017
Hisao Imai
Pleural mesothelioma (PM) is a rare and highly aggressive malignancy originating from the pleural lining, with a median overall survival of merely 1 year. This cancer primarily arises from mesothelial cells following exposure to carcinogenic, biopersistent mineral fibers, particularly asbestos. The histological subtypes of mesothelioma are epithelioid (approximately 60%), sarcomatoid (20%), and biphasic (20%), exhibiting epithelioid and sarcomatoid characteristics. Classification is important for prognosis and guides the therapeutic strategy. Due to the typical late presentation, most patients with PM are ineligible for localized treatments such as surgery or radiotherapy. Systemic therapy, including cytotoxic chemotherapy, targeted therapies, and immunotherapy, is thus critical for managing advanced PM. For unresectable PM, decisions regarding systemic treatment are guided by patient suitability and histological characteristics. First-line therapies for advanced PM currently include the cisplatin–pemetrexed combination and the nivolumab–ipilimumab regimen. Historically, cisplatin–pemetrexed has been administered as first-line treatment, though recent advancements have introduced new therapies that significantly prolong patient survival. Innovative approaches combining immunotherapy and chemotherapy offer promising avenues for further improvement. Future treatment strategies should incorporate novel paradigms, such as combination chemo-immunotherapy, targeted agents, and potential cellular therapies, alongside companion biomarkers tailored to the histologic and molecular diversity of mesothelioma. This review explores the latest advancements in drug therapy for PM and provides an overview of current systemic treatment options.
胸膜间皮瘤(PM)是一种罕见且高度侵袭性的恶性肿瘤,起源于胸膜衬里,中位总生存期仅为1年。这种癌症主要由接触致癌、生物持久性矿物纤维(特别是石棉)后的间皮细胞引起。间皮瘤的组织学亚型为上皮样(约60%)、肉瘤样(20%)和双相(20%),表现为上皮样和肉瘤样特征。分类对预后和指导治疗策略具有重要意义。由于典型的晚期表现,大多数PM患者不适合局部治疗,如手术或放疗。因此,包括细胞毒性化疗、靶向治疗和免疫治疗在内的全身治疗对于治疗晚期PM至关重要。对于不可切除的PM,应根据患者的适宜性和组织学特征来决定是否进行全身治疗。目前晚期PM的一线治疗包括顺铂-培美曲塞联合治疗和尼伏单抗-伊匹单抗方案。从历史上看,顺铂-培美曲塞一直作为一线治疗,尽管最近的进展已经引入了显着延长患者生存期的新疗法。结合免疫治疗和化疗的创新方法为进一步改善提供了有希望的途径。未来的治疗策略应结合新的范例,如化疗-免疫联合治疗、靶向药物和潜在的细胞治疗,以及针对间皮瘤的组织学和分子多样性量身定制的生物标志物。这篇综述探讨了PM药物治疗的最新进展,并提供了当前系统治疗方案的概述。
{"title":"Current drug therapy for pleural mesothelioma","authors":"Hisao Imai","doi":"10.1016/j.resinv.2024.12.017","DOIUrl":"10.1016/j.resinv.2024.12.017","url":null,"abstract":"<div><div>Pleural mesothelioma (PM) is a rare and highly aggressive malignancy originating from the pleural lining, with a median overall survival of merely 1 year. This cancer primarily arises from mesothelial cells following exposure to carcinogenic, biopersistent mineral fibers, particularly asbestos. The histological subtypes of mesothelioma are epithelioid (approximately 60%), sarcomatoid (20%), and biphasic (20%), exhibiting epithelioid and sarcomatoid characteristics. Classification is important for prognosis and guides the therapeutic strategy. Due to the typical late presentation, most patients with PM are ineligible for localized treatments such as surgery or radiotherapy. Systemic therapy, including cytotoxic chemotherapy, targeted therapies, and immunotherapy, is thus critical for managing advanced PM. For unresectable PM, decisions regarding systemic treatment are guided by patient suitability and histological characteristics. First-line therapies for advanced PM currently include the cisplatin–pemetrexed combination and the nivolumab–ipilimumab regimen. Historically, cisplatin–pemetrexed has been administered as first-line treatment, though recent advancements have introduced new therapies that significantly prolong patient survival. Innovative approaches combining immunotherapy and chemotherapy offer promising avenues for further improvement. Future treatment strategies should incorporate novel paradigms, such as combination chemo-immunotherapy, targeted agents, and potential cellular therapies, alongside companion biomarkers tailored to the histologic and molecular diversity of mesothelioma. This review explores the latest advancements in drug therapy for PM and provides an overview of current systemic treatment options.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 2","pages":"Pages 200-209"},"PeriodicalIF":2.4,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LPS-induced TMBIM6 splicing drives endothelial necroptosis and aggravates ALI lps诱导的TMBIM6剪接驱动内皮坏死,加重ALI。
IF 2.4 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-09 DOI: 10.1016/j.resinv.2024.12.016
Yaling Liu , Hao Zhu , Hao Chen , Yang Gao , Tingyin Wang , Xiaodong Wang , Hong Xie

Background

The mechanism underlying necroptosis in pulmonary vessel endothelial cells (PVECs) resulting from long non-coding RNA (lncRNA)-induced alternative splicing (AS) of target genes in acute lung injury (ALI) remains unclear.

Methods

Lipopolysaccharide (LPS)-induced expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and lncRNAs was analyzed via RT-PCR in PVECs. Full-transcriptome sequencing was used to detect AS-related mRNAs. The interaction between lncRNA MALAT1 and target gene transmembrane BAX inhibitor motif-containing 6 (TMBIM6) was verified using a dual-luciferase reporter system. Necroptosis was measured as protein levels of phosphorylated receptor-interacting serine/threonine kinase 1 (RIPK1), RIPK3, and mixed-lineage kinase domain-like (MLKL) proteins, as well as flow cytometer measurement. Antisense of MALAT1, TMBIM6, TMBIM6-225 and RIPK1 inhibitor were transfected into a rat model of LPS-induced ALI. Hematoxylin and eosin (H&E) and immunohistochemical staining were performed to evaluate lung injury.

Results

LPS upregulated the expression of TNF-α, IL-1β, IL-6, p-RIPK1, p-RIPK3, p-MLKL, MALAT1, and TMBIM6-225 (an AS isoform of MALAT1-targeted gene TMBIM6) in PVECs. However, it downregulated the expression of TMBIM6. An antisense of MALAT1 inhibited TMBIM6-225 and downregulated p-MLKL. The pro-necroptotic effect of MALAT1 was verified in an LPS-induced MALAT1/shMALAT1-transfected ALI rat model in vivo. The necroptotic effect was reversed by treatment with necrostatin-1.

Conclusions

LPS-induced MALAT1 causes AS of TMBIM6, and the AS variant TMBIM6-225 aggravates ALI by promoting PVEC necroptosis via the p-RIPK1, p-RIPK3, and p-MLKL complex.
背景:急性肺损伤(ALI)中由长链非编码RNA (lncRNA)诱导的靶基因选择性剪接(AS)导致肺血管内皮细胞(pvec)坏死的机制尚不清楚。方法:采用RT-PCR方法分析脂多糖(LPS)诱导pvec中肿瘤坏死因子(TNF)-α、白细胞介素(IL)-1β、IL-6和lncrna的表达。采用全转录组测序检测as相关mrna。利用双荧光素酶报告系统验证了lncRNA MALAT1与靶基因跨膜BAX抑制剂motif-containing 6 (TMBIM6)之间的相互作用。坏死坏死通过磷酸化受体相互作用丝氨酸/苏氨酸激酶1 (RIPK1)、RIPK3和混合谱系激酶结构域样(MLKL)蛋白水平以及流式细胞仪测量来测量。将MALAT1、TMBIM6、TMBIM6-225和RIPK1抑制剂的反义蛋白转染lps诱导的ALI大鼠模型。采用苏木精和伊红(H&E)染色及免疫组化染色评价肺损伤。结果:LPS上调pevc中TNF-α、IL-1β、IL-6、p-RIPK1、p-RIPK3、p-MLKL、MALAT1和TMBIM6-225 (MALAT1靶向基因TMBIM6的AS亚型)的表达。而下调TMBIM6的表达。MALAT1的反义表达抑制TMBIM6-225,下调p-MLKL。在lps诱导的MALAT1/ shmalat1转染ALI大鼠体内模型中验证了MALAT1的促坏死作用。用坏死他汀-1治疗可逆转坏死作用。结论:lps诱导的MALAT1可引起TMBIM6的AS,而AS变体TMBIM6-225通过p-RIPK1、p-RIPK3和p-MLKL复合物促进PVEC坏死坏死,从而加重ALI。
{"title":"LPS-induced TMBIM6 splicing drives endothelial necroptosis and aggravates ALI","authors":"Yaling Liu ,&nbsp;Hao Zhu ,&nbsp;Hao Chen ,&nbsp;Yang Gao ,&nbsp;Tingyin Wang ,&nbsp;Xiaodong Wang ,&nbsp;Hong Xie","doi":"10.1016/j.resinv.2024.12.016","DOIUrl":"10.1016/j.resinv.2024.12.016","url":null,"abstract":"<div><h3>Background</h3><div>The mechanism underlying necroptosis in pulmonary vessel endothelial cells (PVECs) resulting from long non-coding RNA (lncRNA)-induced alternative splicing (AS) of target genes in acute lung injury (ALI) remains unclear.</div></div><div><h3>Methods</h3><div>Lipopolysaccharide (LPS)-induced expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and lncRNAs was analyzed via RT-PCR in PVECs. Full-transcriptome sequencing was used to detect AS-related mRNAs. The interaction between lncRNA MALAT1 and target gene transmembrane BAX inhibitor motif-containing 6 (TMBIM6) was verified using a dual-luciferase reporter system. Necroptosis was measured as protein levels of phosphorylated receptor-interacting serine/threonine kinase 1 (RIPK1), RIPK3, and mixed-lineage kinase domain-like (MLKL) proteins, as well as flow cytometer measurement. Antisense of MALAT1, TMBIM6, TMBIM6-225 and RIPK1 inhibitor were transfected into a rat model of LPS-induced ALI. Hematoxylin and eosin (H&amp;E) and immunohistochemical staining were performed to evaluate lung injury.</div></div><div><h3>Results</h3><div>LPS upregulated the expression of TNF-α, IL-1β, IL-6, p-RIPK1, p-RIPK3, p-MLKL, MALAT1, and TMBIM6-225 (an AS isoform of MALAT1-targeted gene TMBIM6) in PVECs. However, it downregulated the expression of TMBIM6. An antisense of MALAT1 inhibited TMBIM6-225 and downregulated p-MLKL. The pro-necroptotic effect of MALAT1 was verified in an LPS-induced MALAT1/shMALAT1-transfected ALI rat model <em>in vivo</em>. The necroptotic effect was reversed by treatment with necrostatin-1.</div></div><div><h3>Conclusions</h3><div>LPS-induced MALAT1 causes AS of TMBIM6, and the AS variant TMBIM6-225 aggravates ALI by promoting PVEC necroptosis via the p-RIPK1, p-RIPK3, and p-MLKL complex.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 2","pages":"Pages 191-199"},"PeriodicalIF":2.4,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142954023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive factors of progression in mild fibrosing interstitial lung disease patients with gender-age-physiology score of 3 or less 性别-年龄-生理评分3分及以下轻度纤维化间质性肺病进展的预测因素
IF 2.4 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-01 DOI: 10.1016/j.resinv.2024.12.005
Masaki Okamoto , Kiminori Fujimoto , Tomonori Chikasue , Toyoshi Yanagihara , Kazuhiro Tabata , Yoshiaki Zaizen , Masaki Tominaga , Akiko Sumi , Hiroaki Takeoka , Norikazu Matsuo , Takashi Nouno , Atsushi Kawaguchi , Tomoaki Hoshino

Background

The prognostic factors in mild fibrosing interstitial lung disease (FILD) have not been established.

Methods

We retrospectively attempted to identify predictive factors of annual progression in mild FILD with gender-age-physiology (GAP) score of 3 or less using logistic regression analysis. Annual FILD progression was defined as meeting any two or more of the following conditions: 1, more than 10% decrease in forced vital capacity (FVC) or 15% decrease in diffusing capacity of the lungs for carbon monoxide (DLCO); 2, worsening of dyspnea; 3, worsening of fibrotic change on CT at 1 year after admission.

Results

Univariate analysis showed that diagnosis of connective tissue disease-associated ILD, CT-definite usual interstitial pneumonia (UIP) pattern, composite physiologic index, FVC, DLCO, lowest SpO2 and decrease in SpO2, and walk distance in the 6-minutes walk test (6MWT), chronic pulmonary emphysema assessment test (CAT) score, and some variables in Short-Form 36 were significantly associated with incidence of annual progression. Multivariate analysis showed that independent predictive factors were diagnosis of idiopathic pulmonary fibrosis (IPF) and fibrotic hypersensitivity pneumonitis (HP), CT-definite UIP pattern, lowest SpO2 and decrease in SpO2 in the 6MWT, and CAT score. In logistic regression analysis among 63 patients with non-IPF-ILD, diagnosis with fibrotic HP, lowest SpO2 and decrease in SpO2 in the 6MWT, and CAT score were also independent risk factors for annual FILD progression.

Conclusions

Exercise-induced hypoxia, patient-reported outcome, radiological UIP pattern, and diagnosis with fibrotic HP are independent predictors of annual progression in mild FILD.
背景:轻度纤维化间质性肺病(FILD)的预后因素尚未确定:轻度纤维化间质性肺病(FILD)的预后因素尚未确定:我们采用逻辑回归分析法,回顾性地尝试找出性别-年龄-生理学(GAP)评分为 3 分或更低的轻度 FILD 年度进展的预测因素。每年的 FILD 进展被定义为满足以下任何两个或两个以上条件:1、用力肺活量(FVC)下降超过 10%,或一氧化碳肺弥散容量(DLCO)下降超过 15%;2、呼吸困难加重;3、入院 1 年后 CT 纤维化改变加重:单变量分析表明,结缔组织病相关性 ILD 诊断、CT 定义的寻常间质性肺炎(UIP)模式、综合生理指数、FVC、DLCO、最低 SpO2 和 SpO2 下降、6 分钟步行测试(6MWT)步行距离、慢性肺气肿评估测试(CAT)评分以及短表 36 中的一些变量与年进展发生率显著相关。多变量分析表明,特发性肺纤维化(IPF)和纤维化超敏性肺炎(HP)的诊断、CT-无限UIP模式、6MWT最低SpO2和SpO2下降以及CAT评分是独立的预测因素。在对63名非IPF-ILD患者进行的逻辑回归分析中,纤维化HP诊断、6MWT中最低SpO2和SpO2下降以及CAT评分也是FILD年度进展的独立风险因素:运动引起的缺氧、患者报告的结果、放射学 UIP 模式和纤维化 HP 诊断是轻度 FILD 年度进展的独立预测因素。
{"title":"Predictive factors of progression in mild fibrosing interstitial lung disease patients with gender-age-physiology score of 3 or less","authors":"Masaki Okamoto ,&nbsp;Kiminori Fujimoto ,&nbsp;Tomonori Chikasue ,&nbsp;Toyoshi Yanagihara ,&nbsp;Kazuhiro Tabata ,&nbsp;Yoshiaki Zaizen ,&nbsp;Masaki Tominaga ,&nbsp;Akiko Sumi ,&nbsp;Hiroaki Takeoka ,&nbsp;Norikazu Matsuo ,&nbsp;Takashi Nouno ,&nbsp;Atsushi Kawaguchi ,&nbsp;Tomoaki Hoshino","doi":"10.1016/j.resinv.2024.12.005","DOIUrl":"10.1016/j.resinv.2024.12.005","url":null,"abstract":"<div><h3>Background</h3><div>The prognostic factors in mild fibrosing interstitial lung disease (FILD) have not been established.</div></div><div><h3>Methods</h3><div>We retrospectively attempted to identify predictive factors of annual progression in mild FILD with gender-age-physiology (GAP) score of 3 or less using logistic regression analysis. Annual FILD progression was defined as meeting any two or more of the following conditions: 1, more than 10% decrease in forced vital capacity (FVC) or 15% decrease in diffusing capacity of the lungs for carbon monoxide (D<sub>LCO</sub>); 2, worsening of dyspnea; 3, worsening of fibrotic change on CT at 1 year after admission.</div></div><div><h3>Results</h3><div>Univariate analysis showed that diagnosis of connective tissue disease-associated ILD, CT-definite usual interstitial pneumonia (UIP) pattern, composite physiologic index, FVC, D<sub>LCO</sub>, lowest SpO<sub>2</sub> and decrease in SpO<sub>2</sub>, and walk distance in the 6-minutes walk test (6MWT), chronic pulmonary emphysema assessment test (CAT) score, and some variables in Short-Form 36 were significantly associated with incidence of annual progression. Multivariate analysis showed that independent predictive factors were diagnosis of idiopathic pulmonary fibrosis (IPF) and fibrotic hypersensitivity pneumonitis (HP), CT-definite UIP pattern, lowest SpO<sub>2</sub> and decrease in SpO<sub>2</sub> in the 6MWT, and CAT score. In logistic regression analysis among 63 patients with non-IPF-ILD, diagnosis with fibrotic HP, lowest SpO<sub>2</sub> and decrease in SpO<sub>2</sub> in the 6MWT, and CAT score were also independent risk factors for annual FILD progression.</div></div><div><h3>Conclusions</h3><div>Exercise-induced hypoxia, patient-reported outcome, radiological UIP pattern, and diagnosis with fibrotic HP are independent predictors of annual progression in mild FILD.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 109-117"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis 新型磷酸二酯酶3和4抑制剂ensifentrine治疗慢性阻塞性肺疾病的疗效和安全性:一项系统综述和荟萃分析
IF 2.4 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-01 DOI: 10.1016/j.resinv.2024.12.012
Eeshal Fatima , Obaid Ur Rehman , Zain Ali Nadeem , Umar Akram , Riyan Imtiaz Karamat , Muhammad Omar Larik , Maurish Fatima , Joshua Chitwood , Arslan Ahmad , Sarah Esposito , Abdulqadir J. Nashwan

Background

We evaluated the efficacy and safety of Ensifentrine in COPD via a systematic review and meta-analysis of randomized controlled trials (RCTs).

Methods

We performed a detailed literature search on Medline (via PubMed), Scopus, Google Scholar, and Cochrane on the basis of pre-specified eligibility criteria. We used Review Manager to calculate pooled mean differences (MD) and 95% Confidence Interval (CI) using a random effects model. The Cochrane's Risk of Bias 2 (RoB-2) tool was used to assess the risk of bias in the included RCTs.

Results

A total of 4 studies, consisting of 2020 patients, were included in the meta-analysis. The mean age ranged from 62.5 years to 65.5 years in the included studies. All the included studies were at low risk of bias. Ensifentrine 3 mg dose significantly improved the mean peak Forced Expiratory Volume-1 (FEV-1), morning trough FEV-1, TDI score, ERS score, and SGRQ-C score as compared to the placebo, yielding a pooled MD of 149.76 (95% CI, 127.9 to 171.6), 43.93 (95% CI, 23.82 to 64.05), 0.92 (95% CI, 0.64 to 1.21, −1.20 (95% CI, −1.99 to −0.40), and −1.92 (95% CI, −3.24 to −0.59), respectively.

Conclusion

Ensifentrine is associated with improvements in outcomes related to COPD symptoms such as peak FEV-1, morning trough FEV-1 and TDI in the patients suffering from this chronic disease. It is also associated with improved quality of life as seen by E-RS score and SGRQ-C score.
背景:我们通过随机对照试验(rct)的系统评价和荟萃分析来评估恩西芬汀治疗COPD的疗效和安全性。方法:我们在Medline(通过PubMed)、Scopus、谷歌Scholar和Cochrane上根据预先指定的资格标准进行了详细的文献检索。我们使用Review Manager使用随机效应模型计算汇总平均差异(MD)和95%置信区间(CI)。采用Cochrane's Risk of Bias 2 (rob2)工具评估纳入的rct的偏倚风险。结果:meta分析共纳入4项研究,共纳入2020例患者。在纳入的研究中,患者的平均年龄从62.5岁到65.5岁不等。所有纳入的研究均为低偏倚风险。与安慰剂相比,Ensifentrine 3mg剂量显著改善了平均峰值用力呼气量-1 (FEV-1)、晨间呼气量-1、TDI评分、ERS评分和SGRQ-C评分,合并MD分别为149.76 (95% CI, 127.9 ~ 171.6)、43.93 (95% CI, 23.82 ~ 64.05)、0.92 (95% CI, 0.64 ~ 1.21)、-1.20 (95% CI, -1.99 ~ -0.40)和-1.92 (95% CI, -3.24 ~ -0.59)。结论:在患有慢性疾病的患者中,恩西芬汀与COPD症状相关的结局(如FEV-1峰值、FEV-1晨间低谷和TDI)的改善相关。从E-RS评分和SGRQ-C评分来看,它也与生活质量的改善有关。
{"title":"Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis","authors":"Eeshal Fatima ,&nbsp;Obaid Ur Rehman ,&nbsp;Zain Ali Nadeem ,&nbsp;Umar Akram ,&nbsp;Riyan Imtiaz Karamat ,&nbsp;Muhammad Omar Larik ,&nbsp;Maurish Fatima ,&nbsp;Joshua Chitwood ,&nbsp;Arslan Ahmad ,&nbsp;Sarah Esposito ,&nbsp;Abdulqadir J. Nashwan","doi":"10.1016/j.resinv.2024.12.012","DOIUrl":"10.1016/j.resinv.2024.12.012","url":null,"abstract":"<div><h3>Background</h3><div>We evaluated the efficacy and safety of Ensifentrine in COPD via a systematic review and meta-analysis of randomized controlled trials (RCTs).</div></div><div><h3>Methods</h3><div>We performed a detailed literature search on Medline (via PubMed), Scopus, Google Scholar, and Cochrane on the basis of pre-specified eligibility criteria. We used Review Manager to calculate pooled mean differences (MD) and 95% Confidence Interval (CI) using a random effects model. The Cochrane's Risk of Bias 2 (RoB-2) tool was used to assess the risk of bias in the included RCTs.</div></div><div><h3>Results</h3><div>A total of 4 studies, consisting of 2020 patients, were included in the meta-analysis. The mean age ranged from 62.5 years to 65.5 years in the included studies. All the included studies were at low risk of bias. Ensifentrine 3 mg dose significantly improved the mean peak Forced Expiratory Volume-1 (FEV-1), morning trough FEV-1, TDI score, ERS score, and SGRQ-C score as compared to the placebo, yielding a pooled MD of 149.76 (95% CI, 127.9 to 171.6), 43.93 (95% CI, 23.82 to 64.05), 0.92 (95% CI, 0.64 to 1.21, −1.20 (95% CI, −1.99 to −0.40), and −1.92 (95% CI, −3.24 to −0.59), respectively.</div></div><div><h3>Conclusion</h3><div>Ensifentrine is associated with improvements in outcomes related to COPD symptoms such as peak FEV-1, morning trough FEV-1 and TDI in the patients suffering from this chronic disease. It is also associated with improved quality of life as seen by E-RS score and SGRQ-C score.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 146-155"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and causes of subacute cough in Japan 日本亚急性咳嗽的流行和原因。
IF 2.4 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-01 DOI: 10.1016/j.resinv.2024.11.007
Yoshihisa Ishiura , Masaki Fujimura , Haruhiko Ogawa , Johsuke Hara , Hiromoto Shintani , Soichiro Hozawa , Ryo Atsuta , Kensuke Fukumitsu , Hideki Inoue , Takanobu Shioya , Masato Muraki , Tokunao Amemiya , Noriyuki Ohkura , Yoshitaka Oribe , Hiroshi Tanaka , Takechiyo Yamada , Mikio Toyoshima , Katsuya Fujimori , Tamotsu Ishizuka , Manabu Kagaya , Akio Niimi

Background

Subacute cough is subdivided and distinguished from chronic cough, because post-infectious cough is considered to be the main cause of subacute cough and differs from acute and chronic cough. However, the details of the spectrum and frequency of causes of subacute cough remain unclear because only two studies on subacute cough have been published.

Methods

Patients who presented with cough that lasted for 3–8 weeks and visited respiratory clinics or hospitals affiliated with the Japan Cough Society during 2 years were studied.

Results

A total of 148 patients were prospectively enrolled, and those who did not meet the definition of subacute cough were excluded. Ninety-seven (68.3%) patients with subacute cough progressed to chronic cough, and the main causative diseases were cough variant asthma in 44 patients, atopic cough in 24 patients, sinobronchial syndrome in 13 patients, and post-infectious cough in seven patients. Patients with cough variant asthma complicated by atopic cough and those in whom the cause of subacute cough was unknown tended to develop chronic cough.

Conclusions

This study shows that post-infectious cough is less common than previously thought and the main causes of subacute cough are cough variant asthma, atopic cough, and sinobronchial syndrome and their complications. Cough variant asthma in combination with atopic cough also can be a precursor of refractory chronic cough. The careful diagnosis and treatment of two or more causative diseases is required in patients with subacute cough.
背景:亚急性咳嗽是慢性咳嗽的细分和区别,因为感染后咳嗽被认为是亚急性咳嗽的主要原因,不同于急性和慢性咳嗽。然而,亚急性咳嗽的频谱和频率的细节仍然不清楚,因为只有两个亚急性咳嗽的研究已发表。方法:对2年内就诊于日本咳嗽学会附属医院或呼吸内科的咳嗽持续3 ~ 8周的患者进行研究。结果:共纳入148例患者,排除了不符合亚急性咳嗽定义的患者。亚急性咳嗽发展为慢性咳嗽97例(68.3%),主要病因为咳嗽变异性哮喘44例、特应性咳嗽24例、支气管窦性综合征13例、感染后咳嗽7例。咳嗽变异性哮喘合并特应性咳嗽和亚急性咳嗽病因不明的患者易发展为慢性咳嗽。结论:本研究表明,感染后咳嗽并不常见,亚急性咳嗽的主要原因是咳嗽变异性哮喘、特应性咳嗽和支气管窦综合征及其并发症。咳嗽变异性哮喘合并特应性咳嗽也可能是难治性慢性咳嗽的前兆。亚急性咳嗽患者需要仔细诊断和治疗两种或两种以上的病因。
{"title":"Prevalence and causes of subacute cough in Japan","authors":"Yoshihisa Ishiura ,&nbsp;Masaki Fujimura ,&nbsp;Haruhiko Ogawa ,&nbsp;Johsuke Hara ,&nbsp;Hiromoto Shintani ,&nbsp;Soichiro Hozawa ,&nbsp;Ryo Atsuta ,&nbsp;Kensuke Fukumitsu ,&nbsp;Hideki Inoue ,&nbsp;Takanobu Shioya ,&nbsp;Masato Muraki ,&nbsp;Tokunao Amemiya ,&nbsp;Noriyuki Ohkura ,&nbsp;Yoshitaka Oribe ,&nbsp;Hiroshi Tanaka ,&nbsp;Takechiyo Yamada ,&nbsp;Mikio Toyoshima ,&nbsp;Katsuya Fujimori ,&nbsp;Tamotsu Ishizuka ,&nbsp;Manabu Kagaya ,&nbsp;Akio Niimi","doi":"10.1016/j.resinv.2024.11.007","DOIUrl":"10.1016/j.resinv.2024.11.007","url":null,"abstract":"<div><h3>Background</h3><div>Subacute cough is subdivided and distinguished from chronic cough, because post-infectious cough is considered to be the main cause of subacute cough and differs from acute and chronic cough. However, the details of the spectrum and frequency of causes of subacute cough remain unclear because only two studies on subacute cough have been published.</div></div><div><h3>Methods</h3><div>Patients who presented with cough that lasted for 3–8 weeks and visited respiratory clinics or hospitals affiliated with the Japan Cough Society during 2 years were studied.</div></div><div><h3>Results</h3><div>A total of 148 patients were prospectively enrolled, and those who did not meet the definition of subacute cough were excluded. Ninety-seven (68.3%) patients with subacute cough progressed to chronic cough, and the main causative diseases were cough variant asthma in 44 patients, atopic cough in 24 patients, sinobronchial syndrome in 13 patients, and post-infectious cough in seven patients. Patients with cough variant asthma complicated by atopic cough and those in whom the cause of subacute cough was unknown tended to develop chronic cough.</div></div><div><h3>Conclusions</h3><div>This study shows that post-infectious cough is less common than previously thought and the main causes of subacute cough are cough variant asthma, atopic cough, and sinobronchial syndrome and their complications. Cough variant asthma in combination with atopic cough also can be a precursor of refractory chronic cough. The careful diagnosis and treatment of two or more causative diseases is required in patients with subacute cough.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 74-80"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Direct hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort study 用多粘菌素 B 固定纤维柱(PMX)直接血液灌流治疗特发性肺纤维化急性加重:一项前瞻性多中心队列研究。
IF 2.4 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-01 DOI: 10.1016/j.resinv.2024.11.017
Shinji Abe , Arata Azuma , Yoshinobu Saito , Hiroki Hayashi , Takeru Kashiwada , Toru Tanaka , Tomohisa Baba , Akimasa Sekine , Hideya Kitamura , Ryo Okuda , Satoshi Ikeda , Takashi Ogura

Background

The prognosis of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is extremely poor. However, recent clinical reports suggest that direct hemoperfusion with polymyxin B-immobilized fiber column (PMX) treatment may have beneficial effects in patients with AE-IPF. The aim of this multicenter prospective study was to investigate the effectiveness and safety of PMX treatment in AE-IPF.

Methods

We conducted a prospective study of patients with AE-IPF treated by PMX at two institutions in Japan. Each patient received 2–3 sessions of PMX treatment with a target duration of 6–24 h. The primary endpoint was the survival rate at day 28 after the PMX treatment.

Results

The survival rate of the patients on day 28 after PMX treatment was 65% [95% confidence interval (CI): 40.3–81.5%]. The lower limit of 95% CI in the study was higher than the survival rate of 40%, which was the upper limit of the survival rate in AE-IPF receiving conventional treatments, as reported previously. The survival rate of the patients 12 weeks after PMX was 50% (95% CI: 27.1–69.2%). The changes in the difference between alveolar and arterial oxygen tension and the partial pressure of arterial oxygen/fraction of inspired oxygen improved as the number of PMX sessions increased, and significant improvements were observed at the end of the second PMX session. The safety of PMX was clinically acceptable.

Conclusions

This prospective multicenter study suggests that PMX treatment is safe for patients with AE-IPF and may improve their oxygenation and prognosis.
背景:特发性肺纤维化急性加重期(AE-IPF)的预后极差:特发性肺纤维化急性加重期(AE-IPF)的预后极差。然而,最近的临床报告表明,用多粘菌素 B-固定化纤维柱(PMX)直接进行血液灌流治疗可能对 AE-IPF 患者有益。这项多中心前瞻性研究旨在探讨 PMX 治疗 AE-IPF 的有效性和安全性:我们在日本的两家医疗机构对接受 PMX 治疗的 AE-IPF 患者进行了前瞻性研究。每位患者接受 2-3 次 PMX 治疗,目标疗程为 6-24 小时,主要终点是 PMX 治疗后第 28 天的存活率:PMX治疗后第28天患者的存活率为65%[95%置信区间(CI):40.3-81.5%]。研究中95% CI的下限高于40%的存活率,而40%是之前报道的接受常规治疗的AE-IPF存活率的上限。PMX 治疗 12 周后患者的存活率为 50%(95% CI:27.1%-69.2%)。肺泡和动脉血氧张力之差以及动脉血氧分压/吸入氧分压的变化随着PMX疗程次数的增加而改善,在第二次PMX疗程结束时观察到显著改善。PMX 的安全性在临床上是可以接受的:这项前瞻性多中心研究表明,PMX治疗对AE-IPF患者是安全的,并可改善他们的氧合和预后。
{"title":"Direct hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort study","authors":"Shinji Abe ,&nbsp;Arata Azuma ,&nbsp;Yoshinobu Saito ,&nbsp;Hiroki Hayashi ,&nbsp;Takeru Kashiwada ,&nbsp;Toru Tanaka ,&nbsp;Tomohisa Baba ,&nbsp;Akimasa Sekine ,&nbsp;Hideya Kitamura ,&nbsp;Ryo Okuda ,&nbsp;Satoshi Ikeda ,&nbsp;Takashi Ogura","doi":"10.1016/j.resinv.2024.11.017","DOIUrl":"10.1016/j.resinv.2024.11.017","url":null,"abstract":"<div><h3>Background</h3><div>The prognosis of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is extremely poor. However, recent clinical reports suggest that direct hemoperfusion with polymyxin B-immobilized fiber column (PMX) treatment may have beneficial effects in patients with AE-IPF. The aim of this multicenter prospective study was to investigate the effectiveness and safety of PMX treatment in AE-IPF.</div></div><div><h3>Methods</h3><div>We conducted a prospective study of patients with AE-IPF treated by PMX at two institutions in Japan. Each patient received 2–3 sessions of PMX treatment with a target duration of 6–24 h. The primary endpoint was the survival rate at day 28 after the PMX treatment.</div></div><div><h3>Results</h3><div>The survival rate of the patients on day 28 after PMX treatment was 65% [95% confidence interval (CI): 40.3–81.5%]. The lower limit of 95% CI in the study was higher than the survival rate of 40%, which was the upper limit of the survival rate in AE-IPF receiving conventional treatments, as reported previously. The survival rate of the patients 12 weeks after PMX was 50% (95% CI: 27.1–69.2%). The changes in the difference between alveolar and arterial oxygen tension and the partial pressure of arterial oxygen/fraction of inspired oxygen improved as the number of PMX sessions increased, and significant improvements were observed at the end of the second PMX session. The safety of PMX was clinically acceptable.</div></div><div><h3>Conclusions</h3><div>This prospective multicenter study suggests that PMX treatment is safe for patients with AE-IPF and may improve their oxygenation and prognosis.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 102-108"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between the HAL score and the development of progressive pulmonary fibrosis in idiopathic interstitial pneumonia: A prospective observational study HAL评分与特发性间质性肺炎进展性肺纤维化的相关性:一项前瞻性观察研究
IF 2.4 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-01 DOI: 10.1016/j.resinv.2024.12.011
Hiromasa Nakayasu , Masato Karayama , Noriyuki Enomoto , Yusuke Inoue , Hideki Yasui , Yuzo Suzuki , Hironao Hozumi , Kazuki Furuhashi , Masato Kono , Mikio Toyoshima , Shiro Imokawa , Masato Fujii , Taisuke Akamatsu , Naoki Koshimizu , Koshi Yokomura , Hiroyuki Matsuda , Yusuke Kaida , Yutaro Nakamura , Masahiro Shirai , Masafumi Masuda , Takafumi Suda

Background

Progressive pulmonary fibrosis (PPF) is a critical concern in interstitial lung disease (ILD) management. The HAL score, which incorporates honeycombing (H), age >75 years (A), and serum lactate dehydrogenase >222 U/L (L), can predict acute exacerbations in patients with idiopathic interstitial pneumonia (IIP). This study aims to evaluate the predictive utility of the HAL score for PPF development.

Methods

This study was a post-hoc analysis of a multicenter prospective cohort study involving patients with IIP. PPF was diagnosed if at least two of the following three criteria were met: worsening respiratory symptoms, radiological progression, and physiological progression.

Results

Among the 144 patients, 29 (22.3%) developed PPF during the observation period. Among the three criteria for PPF, a higher HAL score significantly correlated with worsening respiratory symptoms (p = 0.001) and radiological progression (p = 0.022), but not with physiological progression (p = 0.717). Therefore, a higher HAL score significantly correlated with an increased PPF risk (12.5% for a score of 0, 25.9% for a score of 1, and 33.3% for a score of ≥2; p = 0.032). The HAL score also correlated with overall survival (p < 0.001). For the 92 patients (70.8%) with non-idiopathic pulmonary fibrosis (IPF), the HAL score was significantly associated with PPF development (p = 0.021), while not for the 38 patients (29.2%) with IPF (p = 0.872).

Conclusion

In patients with non-IPF, the HAL score correlated with PPF development and could be useful to monitor those patients and to avoid missed treatment opportunities.
背景:进行性肺纤维化(PPF)是间质性肺疾病(ILD)治疗的关键问题。HAL评分包括蜂窝(H)、年龄> ~ 75岁(A)和血清乳酸脱氢酶>222 U/L (L),可以预测特发性间质性肺炎(IIP)患者的急性加重。本研究旨在评估HAL评分对PPF发展的预测效用。方法:本研究是一项涉及IIP患者的多中心前瞻性队列研究的事后分析。如果满足以下三个标准中的至少两个,则诊断为PPF:呼吸系统症状恶化,放射学进展和生理进展。结果:144例患者中,29例(22.3%)在观察期内发生PPF。在PPF的三个诊断标准中,HAL评分越高与呼吸道症状恶化(p = 0.001)和影像学进展(p = 0.022)显著相关,而与生理进展无关(p = 0.717)。因此,较高的HAL评分与PPF风险增加显著相关(得分为0分为12.5%,得分为1分为25.9%,得分≥2分为33.3%;p = 0.032)。HAL评分也与总生存率相关(p结论:在非ipf患者中,HAL评分与PPF发展相关,可用于监测这些患者并避免错过治疗机会。
{"title":"Association between the HAL score and the development of progressive pulmonary fibrosis in idiopathic interstitial pneumonia: A prospective observational study","authors":"Hiromasa Nakayasu ,&nbsp;Masato Karayama ,&nbsp;Noriyuki Enomoto ,&nbsp;Yusuke Inoue ,&nbsp;Hideki Yasui ,&nbsp;Yuzo Suzuki ,&nbsp;Hironao Hozumi ,&nbsp;Kazuki Furuhashi ,&nbsp;Masato Kono ,&nbsp;Mikio Toyoshima ,&nbsp;Shiro Imokawa ,&nbsp;Masato Fujii ,&nbsp;Taisuke Akamatsu ,&nbsp;Naoki Koshimizu ,&nbsp;Koshi Yokomura ,&nbsp;Hiroyuki Matsuda ,&nbsp;Yusuke Kaida ,&nbsp;Yutaro Nakamura ,&nbsp;Masahiro Shirai ,&nbsp;Masafumi Masuda ,&nbsp;Takafumi Suda","doi":"10.1016/j.resinv.2024.12.011","DOIUrl":"10.1016/j.resinv.2024.12.011","url":null,"abstract":"<div><h3>Background</h3><div>Progressive pulmonary fibrosis (PPF) is a critical concern in interstitial lung disease (ILD) management. The HAL score, which incorporates honeycombing (H), age &gt;75 years (A), and serum lactate dehydrogenase &gt;222 U/L (L), can predict acute exacerbations in patients with idiopathic interstitial pneumonia (IIP). This study aims to evaluate the predictive utility of the HAL score for PPF development.</div></div><div><h3>Methods</h3><div>This study was a post-hoc analysis of a multicenter prospective cohort study involving patients with IIP. PPF was diagnosed if at least two of the following three criteria were met: worsening respiratory symptoms, radiological progression, and physiological progression.</div></div><div><h3>Results</h3><div>Among the 144 patients, 29 (22.3%) developed PPF during the observation period. Among the three criteria for PPF, a higher HAL score significantly correlated with worsening respiratory symptoms (<em>p</em> = 0.001) and radiological progression (<em>p</em> = 0.022), but not with physiological progression (<em>p</em> = 0.717). Therefore, a higher HAL score significantly correlated with an increased PPF risk (12.5% for a score of 0, 25.9% for a score of 1, and 33.3% for a score of ≥2; <em>p</em> = 0.032). The HAL score also correlated with overall survival (<em>p</em> &lt; 0.001). For the 92 patients (70.8%) with non-idiopathic pulmonary fibrosis (IPF), the HAL score was significantly associated with PPF development (<em>p</em> = 0.021), while not for the 38 patients (29.2%) with IPF (<em>p</em> = 0.872).</div></div><div><h3>Conclusion</h3><div>In patients with non-IPF, the HAL score correlated with PPF development and could be useful to monitor those patients and to avoid missed treatment opportunities.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 138-145"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The utility and safety of one-minute sit-to-stand test in pulmonary hypertension: A prospective study 肺动脉高压1分钟坐立试验的有效性和安全性:一项前瞻性研究。
IF 2.4 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-01 DOI: 10.1016/j.resinv.2024.12.003
Kenichiro Takeda , Ayako Shigeta , Takeshi Inagaki , Nami Hayama , Chiaki Kawame , Yasuyuki Naraki , Akira Naito , Ayumi Sekine , Rika Suda , Toshihiko Sugiura , Nobuhiro Tanabe , Takuji Suzuki

Background

Functional exercise capacity in pulmonary hypertension (PH) is routinely assessed using the 6-min walking test (6MWT). However, alternative tests are useful because of resource requirements. This study aimed to evaluate whether the 1-min sit-to-stand test (1STST) is useful and safe in PH and whether it can replace the 6MWT.

Methods

Adult patients with PH were recruited from our hospital between September 2023 and April 2024. The correlations between the number of 1STST repetitions (1STSTr) and 6-min walk distance (6MWD), pulmonary hemodynamic parameters, and quadriceps muscle strength; adverse events; and vital sign fluctuations during the tests were evaluated, and a questionnaire with an 11-point Likert scale (−5, 6MWT favor; 5, 1STST favor) was administered.

Results

Twenty-one patients with PH were enrolled in this study. The 1STSTr and 6MWD were 23.8 ± 7.8/min and 425.8 ± 116.8 m, respectively, with a strong correlation (r = 0.771). 1STSTr was significantly correlated with brain natriuretic peptide, but not with other pulmonary hemodynamic markers, respiratory function, or quadriceps muscle strength. No serious adverse events or motor impairments occurred with the 1STST.
The minimum SpO2 during the tests was significantly lower with the 6MWT (92.6 ± 3.1 vs. 88.0 ± 11.0). The questionnaire showed a predominant preference for the 1STST (3.2 ± 2.6).

Conclusions

To our knowledge, this is the first study in Japan to adapt the 1STST to PH patients. The 1STST is a reliable alternative to the 6MWT for measuring exercise capacity in PH patients.

Trial registration

This study was registered with the UMIN-CTR (number UMIN000052010).
背景:肺动脉高压(PH)患者的功能性运动能力通常通过6分钟步行试验(6MWT)进行评估。但是,由于资源需求,替代测试是有用的。本研究旨在评估1分钟坐立试验(1STST)在PH下是否有用和安全,是否可以取代6MWT。方法:于2023年9月至2024年4月在我院招募成年PH患者。1STST重复次数(1STSTr)与6分钟步行距离(6MWD)、肺血流动力学参数、股四头肌力量的相关性;不良事件;并采用李克特11分量表(- 5,6 mwt赞成;5, 1STST支持)。结果:21例PH患者入组本研究。1STSTr和6MWD分别为23.8±7.8 m /min和425.8±116.8 m,相关性较强(r = 0.771)。1STSTr与脑利钠肽显著相关,但与其他肺血流动力学指标、呼吸功能或股四头肌力量无关。1STST未发生严重不良事件或运动障碍。试验期间的最小SpO2明显低于6MWT(92.6±3.1 vs. 88.0±11.0)。问卷调查结果显示,1STST(3.2±2.6)占主导地位。结论:据我们所知,这是日本第一个将1STST应用于PH患者的研究。1STST是测量PH患者运动能力的可靠替代方案。试验注册:本研究已在UMIN-CTR注册(编号为UMIN000052010)。
{"title":"The utility and safety of one-minute sit-to-stand test in pulmonary hypertension: A prospective study","authors":"Kenichiro Takeda ,&nbsp;Ayako Shigeta ,&nbsp;Takeshi Inagaki ,&nbsp;Nami Hayama ,&nbsp;Chiaki Kawame ,&nbsp;Yasuyuki Naraki ,&nbsp;Akira Naito ,&nbsp;Ayumi Sekine ,&nbsp;Rika Suda ,&nbsp;Toshihiko Sugiura ,&nbsp;Nobuhiro Tanabe ,&nbsp;Takuji Suzuki","doi":"10.1016/j.resinv.2024.12.003","DOIUrl":"10.1016/j.resinv.2024.12.003","url":null,"abstract":"<div><h3>Background</h3><div>Functional exercise capacity in pulmonary hypertension (PH) is routinely assessed using the 6-min walking test (6MWT). However, alternative tests are useful because of resource requirements. This study aimed to evaluate whether the 1-min sit-to-stand test (1STST) is useful and safe in PH and whether it can replace the 6MWT.</div></div><div><h3>Methods</h3><div>Adult patients with PH were recruited from our hospital between September 2023 and April 2024. The correlations between the number of 1STST repetitions (1STSTr) and 6-min walk distance (6MWD), pulmonary hemodynamic parameters, and quadriceps muscle strength; adverse events; and vital sign fluctuations during the tests were evaluated, and a questionnaire with an 11-point Likert scale (−5, 6MWT favor; 5, 1STST favor) was administered.</div></div><div><h3>Results</h3><div>Twenty-one patients with PH were enrolled in this study. The 1STSTr and 6MWD were 23.8 ± 7.8/min and 425.8 ± 116.8 m, respectively, with a strong correlation (<em>r</em> = 0.771). 1STSTr was significantly correlated with brain natriuretic peptide, but not with other pulmonary hemodynamic markers, respiratory function, or quadriceps muscle strength. No serious adverse events or motor impairments occurred with the 1STST.</div><div>The minimum SpO<sub>2</sub> during the tests was significantly lower with the 6MWT (92.6 ± 3.1 vs. 88.0 ± 11.0). The questionnaire showed a predominant preference for the 1STST (3.2 ± 2.6).</div></div><div><h3>Conclusions</h3><div>To our knowledge, this is the first study in Japan to adapt the 1STST to PH patients. The 1STST is a reliable alternative to the 6MWT for measuring exercise capacity in PH patients.</div></div><div><h3>Trial registration</h3><div>This study was registered with the UMIN-CTR (number UMIN000052010).</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 61-66"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of intrabronchial local anesthesia with a spray catheter and continuous oral suction in reducing cough during bronchoscopy: A prospective study 支气管局部麻醉雾化导管和持续口腔吸痰在支气管镜检查中减少咳嗽的有效性:一项前瞻性研究。
IF 2.4 Q2 RESPIRATORY SYSTEM Pub Date : 2025-01-01 DOI: 10.1016/j.resinv.2024.12.002
Kazuo Tsuchiya, Tomotsugu Nuki, Tomo Tsunoda, Taisuke Ito, Rie Mori, Takuro Akashi, Yoshiyuki Oyama, Masaki Ikeda

Background

Coughing and other distress during bronchoscopy are undesirable for both patients and bronchoscopists. The efficacy of local anesthetics administered via aerosol sprays in the airways has been documented; however, the optimal administration method remains unclear. Furthermore, the efficacy of continuous salivary aspiration in reducing cough and other distress has not yet been evaluated.

Methods

Patients scheduled for bronchoscopy were assigned to 1 of 4 groups—group A (intrabronchial local anesthesia using a syringe without continuous oral suction); group B (intrabronchial local anesthesia using a spray catheter without continuous oral suction); group C (intrabronchial local anesthesia using a syringe with continuous oral suction using a saliva ejector); group D (intrabronchial local anesthesia using a spray catheter with continuous oral suction using a saliva ejector). The distress levels of the patients were evaluated using a questionnaire with a visual analog scale, and cough counts were quantified during bronchoscopy. Additionally, we assessed the total amount of lidocaine consumed and changes in vital signs.

Results

Local anesthesia in the airway using a spray catheter did not reduce patient distress; however, it reduced cough frequency (P = 0.03) and lidocaine dosage (P = 0.0004). Continuous suctioning of saliva did not reduce the patients’ distress or cough frequency.

Conclusion

The use of a spray catheter rather than a syringe is recommended for administering local anesthesia with lidocaine during bronchoscopy. Conversely, continuous suctioning of saliva is not routinely recommended for all patients.
背景:支气管镜检查时咳嗽和其他不适对患者和支气管镜医师都是不可取的。局部麻醉药通过气雾喷雾在气道中施用的有效性已被记录;然而,最佳给药方法尚不清楚。此外,持续唾液吸吸在减少咳嗽和其他痛苦方面的疗效尚未得到评估。方法:将拟行支气管镜检查的患者分为1组,共4组:A组(支气管局部麻醉,使用注射器,不进行连续口腔吸痰);B组(支气管局部麻醉,使用喷雾导管,不持续口腔吸痰);C组(支气管局部麻醉,使用注射器持续口腔吸痰);D组(支气管局部麻醉,使用喷雾导管,使用唾液喷射器持续口腔吸引)。采用带有视觉模拟量表的问卷评估患者的痛苦程度,并对支气管镜检查期间的咳嗽计数进行量化。此外,我们评估了利多卡因消耗总量和生命体征的变化。结果:气道局部麻醉使用喷雾导管不能减轻患者的痛苦;而咳嗽频次(P = 0.03)和利多卡因用量(P = 0.0004)明显降低。持续吸痰并不能减轻患者的痛苦和咳嗽频率。结论:在支气管镜检查过程中,利多卡因局部麻醉推荐使用喷雾导管而不是注射器。相反,并非所有患者都常规推荐持续吸痰。
{"title":"Effectiveness of intrabronchial local anesthesia with a spray catheter and continuous oral suction in reducing cough during bronchoscopy: A prospective study","authors":"Kazuo Tsuchiya,&nbsp;Tomotsugu Nuki,&nbsp;Tomo Tsunoda,&nbsp;Taisuke Ito,&nbsp;Rie Mori,&nbsp;Takuro Akashi,&nbsp;Yoshiyuki Oyama,&nbsp;Masaki Ikeda","doi":"10.1016/j.resinv.2024.12.002","DOIUrl":"10.1016/j.resinv.2024.12.002","url":null,"abstract":"<div><h3>Background</h3><div>Coughing and other distress during bronchoscopy are undesirable for both patients and bronchoscopists. The efficacy of local anesthetics administered via aerosol sprays in the airways has been documented; however, the optimal administration method remains unclear. Furthermore, the efficacy of continuous salivary aspiration in reducing cough and other distress has not yet been evaluated.</div></div><div><h3>Methods</h3><div>Patients scheduled for bronchoscopy were assigned to 1 of 4 groups—group A (intrabronchial local anesthesia using a syringe without continuous oral suction); group B (intrabronchial local anesthesia using a spray catheter without continuous oral suction); group C (intrabronchial local anesthesia using a syringe with continuous oral suction using a saliva ejector); group D (intrabronchial local anesthesia using a spray catheter with continuous oral suction using a saliva ejector). The distress levels of the patients were evaluated using a questionnaire with a visual analog scale, and cough counts were quantified during bronchoscopy. Additionally, we assessed the total amount of lidocaine consumed and changes in vital signs.</div></div><div><h3>Results</h3><div>Local anesthesia in the airway using a spray catheter did not reduce patient distress; however, it reduced cough frequency (<em>P</em> = 0.03) and lidocaine dosage (<em>P</em> = 0.0004). Continuous suctioning of saliva did not reduce the patients’ distress or cough frequency.</div></div><div><h3>Conclusion</h3><div>The use of a spray catheter rather than a syringe is recommended for administering local anesthesia with lidocaine during bronchoscopy. Conversely, continuous suctioning of saliva is not routinely recommended for all patients.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 67-73"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Respiratory investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1